Oral semaglutide (Rybelsus, Novo Nordisk) lowered hemoglobin A1c more than empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) in a recently published open-label, head-to-head comparison of the type ...

WASHINGTON, DC — Use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduced the need for urate-lowering therapy (ULT) and gout flare therapies in people who had both type 2 diabetes (T2D) and ...

Add Yahoo as a preferred source to see more of our stories on Google. The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could be ...

Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...

When diabetes causes CKD, it’s sometimes called diabetic kidney disease. Elevated blood sugar levels that result from diabetes can damage the tiny blood vessels inside your kidneys. As a result, your ...

SELECT was a large study focused on obesity and cardiovascular disease in people without type 2 diabetes, but it included ...

The landscape of diabetes management is undergoing a remarkable transformation. Groundbreaking research has uncovered surprising cardiovascular benefits tied to modern medications, offering new hope ...

Are Diabetes Drugs Really Safe (& Reliable) for Weight Loss? There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight loss. Whether ...

A groundbreaking development in diabetes treatment reveals that SGLT-2 inhibitors significantly reduce dementia risk among type 2 diabetes patients. Recent research demonstrates these medications ...